1. Home
  2. WULF vs IONS Comparison

WULF vs IONS Comparison

Compare WULF & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TeraWulf Inc.

WULF

TeraWulf Inc.

N/A

Current Price

$11.59

Market Cap

6.3B

Sector

Technology

ML Signal

N/A

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

N/A

Current Price

$27.24

Market Cap

6.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WULF
IONS
Founded
1952
1989
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.6B
IPO Year
1999
1996

Fundamental Metrics

Financial Performance
Metric
WULF
IONS
Price
$11.59
$27.24
Analyst Decision
Strong Buy
Buy
Analyst Count
25
25
Target Price
$25.52
★ $67.83
AVG Volume (30 Days)
★ 42.9M
4.1M
Earning Date
11-06-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.71
EPS
★ N/A
N/A
Revenue
★ $168,455,000.00
N/A
Revenue This Year
$43.46
N/A
Revenue Next Year
$257.90
$26.34
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 20.28
N/A
52 Week Low
$9.51
$26.55
52 Week High
$29.84
$86.74

Technical Indicators

Market Signals
Indicator
WULF
IONS
Relative Strength Index (RSI) 45.04 22.17
Support Level $10.31 N/A
Resistance Level $13.56 $46.07
Average True Range (ATR) 1.24 1.99
MACD 0.09 -0.74
Stochastic Oscillator 50.52 2.59

Price Performance

Historical Comparison
WULF
IONS

About WULF TeraWulf Inc.

TeraWulf Inc develops and operates large-scale digital infrastructure designed for AI and high-performance computing workloads. The Company owns and operates energy infrastructure across key U.S. power markets, providing large-scale, contiguous power capacity for next-generation compute. Its strategic sites offer direct grid connectivity and, in select locations, integrated generation, creating a foundation for scalable compute infrastructure. Built on deep expertise in energy markets and grid integration, TeraWulf approaches compute infrastructure from the foundation up- securing power, developing scalable sites, and operating with disciplined execution.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Share on Social Networks: